Abstract 685TiP
Background
Targeted Radiopharmaceutical Therapy (RPT) with [177Lu]Lu-edotreotide is being explored as treatment option for patients with relapsed/refractory somatostatin receptor (SSTR)-positive tumors, including neuroendocrine tumors, CNS-tumors, lymphoma, rhabdomyosarcoma, peripheral primitive neuroectodermal tumors and gastrointestinal sarcoma tumors.
Trial design
KinLET is an open-label, multicenter, phase I trial aiming to determine the appropriate dose based on the safety profile and the pharmacokinetics (PK) of [177Lu]Lu-edotreotide targeted RPT in pediatric patients with SSTR-positive tumors. Further objectives include the assessment of preliminary anti-tumor activity by tumor type, safety and dosimetry evaluations. Up to 100 MBq/kg or 7.5 GBq/75 kg for each treatment cycle will be studied. Dosage of [177Lu]Lu-edotreotide will be adjusted based on the patient's weight as well as dosimetry in a subset of patients and applied sequentially in each cohort to not exceed a total absorbed dose of 23 Gy and 2 Gy to kidneys and bone marrow, respectively. [177Lu]Lu-edotreotide dosimetry is planned to be evaluated by single-photon emission computed tomography/low dose computed tomography; whole body planar imaging and blood radioactivity measurements at specific intervals, along with safety and preliminary efficacy parameters. It is planned to include at least 20 participants in three sequential age cohorts: (1) ≥12 to <18 years old; (2) ≥6 years to <12 years old; (3) ≥2 to <6 years old (minimum of six participants in each age cohort). The opening of the 2nd and 3rd cohort will depend on the recruitment of at least four participants with dosimetry and safety data for cycle 1 of the previous cohort. Treatment will comprise two to six [177Lu]Lu-edotreotide treatment cycles every eight weeks. Tumor assessment and follow-up evaluation by anatomical and functional imaging is performed within the treatment period and the first two years of the five-year follow-up. Due to the rare incidence of SSTR-positive tumors in pediatric patients, patient recruitment is a key element in this trial.
Clinical trial identification
Editorial acknowledgement
Margret I. Moré.
Legal entity responsible for the study
ITM Solucin GmbH.
Funding
ITM Solucin GmbH.
Disclosure
S. Melnyk, T. Thevenet: Financial Interests, Institutional, Full or part-time Employment: ITM Isotope Technologies Munich SE. A. Rotger: Financial Interests, Institutional, Financially compensated role: ITM Isotope Technologies Munich SE. All other authors have declared no conflicts of interest.
Resources from the same session
651P - Phase I study of XNW27011, a novel claudin 18.2 ADC, in patients with locally advanced and/or metastatic solid tumors
Presenter: Jinming Yu
Session: Poster session 01
652P - BT8009 monotherapy in enfortumab vedotin (EV)-naïve patients (pts) with metastatic urothelial carcinoma (mUC): Updated results of Duravelo-1
Presenter: Oscar Reig Torras
Session: Poster session 01
653P - A phase I dose escalation study of EBC-129, a first-in class, anti N-glycosylated CEACAM5 & CEACAM6 antibody-drug conjugate (ADC) in patients with solid tumors
Presenter: Matthew Chau Hsien Ng
Session: Poster session 01
654P - Peripheral neuropathy (PN) following treatment (tx) with bicycle toxin conjugates (BTCs) BT8009 or BT5528 monotherapy in patients (pts) with advanced solid tumors
Presenter: Bernard Doger de Spéville
Session: Poster session 01
655P - Toxicity and efficacy of antibody drug conjugates (ADC) in advanced solid tumors: A pooled analysis of Sarah Cannon UK
Presenter: Rachel Woodford
Session: Poster session 01
656P - Phase I/Ib open-label study of an HER2-targeted T cell engager (TCE)‒SAR443216 in patients (pts) with advanced solid tumors: Intravenous (IV) dose-escalation results
Presenter: Victor Moreno Garcia
Session: Poster session 01
657P - Prospective validation of the T cell engager (TCE) score in patients treated with bispecific CD3 TCE antibodies in phase I clinical trials
Presenter: Noé Herbel
Session: Poster session 01
658P - First-in-human phase I trial of oncolytic herpes simplex virus ONCR-177 alone or in combination with pembrolizumab in advanced solid tumors
Presenter: Cátia Fava Gaspar
Session: Poster session 01
659P - Combination treatment with TTX-030, a first-in-class anti-CD39 antibody, in patients with advanced pancreatic cancer
Presenter: Zev Wainberg
Session: Poster session 01
660P - Atezolizumab plus UCPvax telomerase CD4 TH1-inducer cancer vaccine for the treatment of chemorefractory HPV+ cancers: Safety and efficacy results of the VolATIL phase II study
Presenter: Laura Mansi
Session: Poster session 01